May 18, 2024

Empower Service Hub

Timely Service

Beauty Farm Medical and Health Industry Full Year 2023 Earnings: EPS Misses Expectations

2 min read

Beauty Farm Medical and Health Industry (HKG:2373) Full Year 2023 Results

Key Financial Results

  • Revenue: CN¥2.15b (up 31% from FY 2022).
  • Net income: CN¥215.7m (up 109% from FY 2022).
  • Profit margin: 10% (up from 6.3% in FY 2022). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.94 (up from CN¥0.52 in FY 2022).
SEHK:2373 Revenue and Expenses Breakdown March 28th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beauty Farm Medical and Health Industry EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.1%.

The primary driver behind last 12 months revenue was the Beauty and Wellness Services – Direct Stores segment contributing a total revenue of CN¥1.08b (50% of total revenue). Notably, cost of sales worth CN¥1.17b amounted to 54% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥378.2m (50% of total expenses). Explore how 2373’s revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Consumer Services industry in Hong Kong.

Performance of the Hong Kong Consumer Services industry.

The company’s shares are up 11% from a week ago.

Balance Sheet Analysis

While it’s very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We’ve done some analysis and you can see our take on Beauty Farm Medical and Health Industry’s balance sheet.

Valuation is complex, but we’re helping make it simple.

Find out whether Beauty Farm Medical and Health Industry is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.


Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.